SBDM 05
Alternative Names: SBDM-05Latest Information Update: 26 Aug 2024
At a glance
- Originator Shilpa Biologicals
- Class Anti-ischaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Myocardial infarction
Most Recent Events
- 05 Aug 2024 Early research in Myocardial infarction in India (Parenteral), prior to August 2024 (Shilpa Biologicals pipeline, December 2024)